Cell Therapy Strategy
The Integration Edge
In cell therapy deals, post-signing integration of manufacturing, supply, and clinical operations often decides whether the partnership creates value — well before commercial readiness.
Where most cell therapy partnerships stall
Term sheets close on clinical and commercial rights. Value is realised — or lost — in the eighteen months that follow, when vector supply, fill/finish capacity, and site activation have to be coordinated across two organisations with different operating cultures.
What strong acquirers ask for at LOI
Experienced acquirers front-load integration questions: vector source and second-source plan, apheresis network, QP/QC ownership, and the named individuals who will hold continuity through transition. The strongest sellers prepare answers before they are asked.
A practical integration brief
We typically recommend a short, written integration brief — five to eight pages — circulated in parallel with the data room. It does not replace diligence; it signals operational maturity and shortens the path to a credible offer.
For biotech partnering or asset strategy discussions, contact Kerlann Advisory.